

**AMENDMENTS TO THE SPECIFICATION**


Please replace the English translation of the International Application as filed with the Corrected Literal English Translation of the International application as filed attached to the present paper.

Please replace the paragraph bridging page 1, at line 28 to page 2, line 8 with the following amended paragraph.

As another approach for solution, researches have has been made for providing a microcirculation property and escapability from RES by modification of membrane surfaces of liposomes with a glycolipid, glycoprotein, amino acid-lipid, polyethylene glycol-lipid or the like. Substances for the modification so far reported include, for example, glycophon (The Pharmaceutical Society of Japan, the 106th Annual Meeting, Summaries of Symposia, p. 336, 1986), ganglioside GM1 (FEBS Letters, Vol. 223, p. 42, 1987), phosphatidylinositol (FEBS Letters, Vol. 223, p.42, 1987), glycophon and ganglioside GM3 (Japanese Patent Unexamined Publication (Kokai) No. 63-221837), polyethylene glycol derivative (FEBS Letters, Vol. 268, p.236, 1990), glucuronic acid derivative (Chemical & Pharmaceutical Bulletin, Vol.38, p.1663 p.1633, 1990), glutamic acid derivative (Biochimica et Biophysica Acta, Vol.1108, p.257, 1992), polyglycerin phospholipids derivative (Japanese Patent Unexamined Publication No. 6-228012), and the like.

Please replace the paragraph bridging pages 4 and 5 with the following amended paragraph:

From a further aspect, the present invention provides a method for producing the aforementioned phospholipid derivative, which comprises the step of reacting a copolymer containing the component unit A and the component unit B at a molar ratio of 7/3 to 3/7 with a compound represented by the following formula (4):



wherein R<sup>5</sup>CO, R<sup>6</sup>CO, R<sup>7</sup> and Y have the same meanings as those defined above.